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Scientifically unfounded precaution drives  
European Commission’s recommendations on  
EDC regulation, while defying common sense,  
well-established science and risk assessment 
principles
We, the undersigned editors of prominent journals of pharma-
cology and toxicology, are drawing your attention to the immi-
nent decisions by the european Commission to enforce a regu-
latory framework for so-called endocrine disrupting chemicals 
(eDCs). the currently drafted framework is based on virtually 
complete ignorance of all well-established and taught princi-
ples of pharmacology and toxicology, of opinions raised by the 
european Commission’s own competent expert authority (eu-
ropean Food Safety Authority (eFSA, 2013)), and of critical 
statements made by member countries, while avoiding asking 
for support from the European Commission’s own scientific 
expert committees. 
As a statement, and as emphasized by others before, “endo-
crine disruption” is not a toxicologically defined endpoint but a 
mode-of-action that may or may not result in adverse effects. In 
itself, the mode-of-action concept implies the necessary exist-
ence of a threshold as experimentally proven for numerous oth-
er non-genotoxic agents including eDC’s. Moreover, endocrine 
systems play a fundamental role in the physiological response 
to changes in the environment with the aim of keeping an or-
ganism’s biology within the homeostatic space. It is the task of 
toxicologists to make the distinction between those effects that 
are within this adaptive range and effects that go beyond the 
boundaries of this space and thus can be called adverse. Such 
adverse effects can be observed in adequately designed and per-
formed toxicity studies. 
While we agree that a concern for possible eDCs is sensible 
and important, we also think that the identification and regula-
tion of such substances should depend on a) the definition of ad-
verse effects that are relevant to whole human or animal organ-
isms and not to isolated test systems of unknown homeostatic 
significance, and b) on a characterization of real-life potency 
and therefore of thresholds of concern. 
In contrast, the currently drafted eU framework for eDCs 
foresees a priori regulation of agents that may show presum-
ably endocrine-mediated effects in some experimental system 
(in vitro, in silico, in vivo…), and under the a priori default 
assumption of no thresholds. this approach is based on a very 
small number of publications (Sheehan, 2006; Vandenberg et 
al., 2012; Zoeller et al., 2012; Birnbaum, 2013) that lack the re-
quired scientific robustness needed for such an important piece 
of legislation that is sweeping in nature, will set an unforeseen 
precedence, and finally will have profound ramifications for 
everyone’s livelihood. Furthermore, the regulatory draft specif-
ically states that the identification of an endocrine disruptor re-
lies “on the demonstration of an adverse effect for which there 
is convincing evidence of a biologically plausible causal link to 
an endocrine disrupting mode of action and for which disrup-
tion of the endocrine system is not a secondary consequence of 
other non endocrine-mediated systemic toxicity. Relevance of 
the data to humans should be assumed in the absence of ap-
propriate data demonstrating non-relevance.” 
As all scientists should know, it is biologically and statisti-
cally impossible to demonstrate “absence of effect” and thus 
“absence of relevance”. the mere statement demonstrates 
the lack of attention paid by the european Commission to the 
weight of scientific evidence that clearly demonstrates the 
presence of a threshold for non-genotoxic compounds includ-
ing eDCs (Rhomberg et al., 2011, 2012; Borgert et al., 2012; 
Piersma et al., 2011; Boobis et al., 2009), as well as to the 
scientific detail with regard to the physiological and statisti-
cal implausibility of the approach taken. In fact, any scientist 
familiar with the overwhelming biochemical complexity of 
life understands that the healthy homeostasis of an organism 
results from an orchestrated network of myriad thresholds for 
every component substance.
On this account, a nucleus of scientists sent an open letter on 
June 18 20131 to Prof. Anne Glover, Chief Scientific Advisor to 
the President of the european Commission Manuel Barroso2, 
pointing out the major deficiencies of the drafted EU frame-
work, and the worrisome ramifications this draft could have for 
science, the economy, and human welfare the world over.
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Although some readers may shrug and think this is not im-
portant and not their problem, it soon could be. Regulations that 
profoundly affect human activities, that legally impose signifi-
cant fines and even detention, should not be based on irrelevant 
tests forced to be regarded as relevant by administrative dictates, 
and on arbitrary default assumptions of no thresholds. Such 
standards would be contrary not only to science, but to the very 
principles of an enlightened governance and social contract. Not 
only scientists but society itself would pay dearly if unscientific 
approaches were to undermine our everyday practice of science, 
and the stringency of data analysis and evaluation developed by 
scientific thinking over the past centuries. In the present instance, 
the very credibility of thorough and robust teaching, research, 
and scientific analysis is questioned. This calls for action, and as 
beneficiaries of public support it is the utmost responsibility of 
us scientists to resist and counteract any efforts that undermine 
the core of science and its continuing promise for the betterment 
of the human condition and of the planet. 
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tification of an in vitro effect without a causal relationship to 
adversity in an intact organism may be sufficient to classify a 
substance as an “endocrine disruptor”. this would not only rep-
resent a rewriting of the rules and accepted practices of toxi-
cology, which rely on well- defined adverse effects observed in 
adequately performed studies, but also would be contrary to all 
accumulated physiological understanding. 
This leaves us concerned that there is neither a scientific basis 
nor broad support by scientists established in risk assessment 
behind the approach of setting horizontal criteria and the lists of 
confirmed and suspected “endocrine disruptors”.
We have noted your important interventions on the need 
for scientific evidence to be at the heart of EU policy and are 
therefore writing to urge your review of the emerging policy 
to ensure that the opinion of relevant scientific committees and 
member states authorities are taken into account.
the following individuals are supporting this initiative:
Antero Aitio, Dr. Med. Sc., Professor h.c., former scientist/
medical officer at the International Programme on Chemi-
cal Safety, World Health Organization; former team leader, 
Finnish Institute of Occupational Health; former Unit Chief 
of the Monographs Programme, International Agency for 
Research on Cancer 
Herman Autrup, Professor, PhD AtS, President International 
Union of toxicologists, former member SCHeR, AFC- Panel 
of eFSA, Institute of Public Health, University of Aarhus, 
Denmark
Susan, Barlow, Ph.D., former member of EFSA Scientific 
Committee (2003- 2012), Brighton, UK
Diane Benford, Dr., member, chair CONtAM Panel of eFSA, 
Head of Chemical Risk Assessment Unit, Food Standards 
Agency, london, UK
Ole J. Bjerrum, DMSc, Professor of Pharmacology, University 
of Copenhagen, Denmark
Sir Colin Berry, Prof. emeritus of Pathology, Queen Mary, 
University of london, UK
Bas J. Blaauboer, Prof. Dr., Doerenkamp- Zbinden Chair on 
Alternatives to toxicity testing, Institute for Risk Assess-
ment Sciences, Division of toxicology, Utrecht University, 
the Netherlands
Dear Prof. Glover, 
We, the undersigned are writing to draw your attention to immi-
nent decisions by the european Commission to set a regulatory 
framework for so- called endocrine disrupting chemicals. We 
are concerned that the approach proposed could rewrite well-
 accepted scientific and regulatory principles in the areas of toxi-
cology and ecotoxicology without adequate scientific evidence 
justifying such a departure from existing practices. 
First of all, we want to emphasize that “endocrine disruption” 
is not a toxicological endpoint, but one of many mechanisms 
which may cause adverse effects. In addition, we recognise that 
such a policy initiative is highly technical and complex and re-
quires an understanding of the modes of action for endocrine 
disruption and their significance. It also implies the in- depth 
involvement not only of toxicological disciplines but also of 
environmental sciences and thus requires scientific input 
from experts in this area. the undersigned are concerned that 
the Commission’s scientific committees have so far not been 
consulted by the Commission when drafting such regulations. 
What is even more disturbing is that, where a scientific advi-
sory body such as eFSA has been consulted, critical elements 
of this body’s opinion are ignored. For example, in assessment 
of chemicals with endocrine activity, eFSA supported a sub-
stance specific risk assessment approach integrating exposure 
and adverse effects instead of developing horizontal criteria 
for defining whether a substance is an “endocrine disruptor”. 
Development of horizontal lists ignores the long- standing prin-
ciple that an assessment of a substance should be based on data 
obtained from toxicity testing on this specific substance and 
derived information on potency. 
If the Commission will adopt a policy stating that it is im-
possible to define a safe limit or threshold for a substance with 
classified as endocrine disruptor, this would reverse current sci-
entific and regulatory practices and, more importantly, ignore 
broadly developed and accepted scientific development and ac-
cepted knowledge regarding thresholds of adversity. Moreover, 
the latter approach may not only apply to potential eDCs but 
rather would apply to all chemical substances and thus nullify 
decades of experience and repeatable observations in exposure-
 response relationships in pharmacology and toxicology and 
well- established and widely proven procedures in hazard and 
risk assessment. 
It also appears that the Commission will propose that iden-
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Department of Biology, University of Konstanz, Germany
Michèle Bouchard, Ph.D., Associate Professor, Head of the 
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thomas Colnot, Ph.D., eRt, CiS toxicology, Castro, Chile
Brian Cummings, Ph.D., Assistant Professor, Department of 
Pharmaceutical and Biomedical Sciences, University of 
Georgia, Athens, GA, USA
Slawomir Czerczak, Prof. Dr., Chair for Group of experts 
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Wolfgang Dekant, PhD, Professor of toxicology, former mem-
ber SCHeR, CStee, member SCHeNIHR, Department of 
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Marco Vighi, Prof. Dr., former member SCHeR, Department 
of earth and environmental Sciences, University of Milano 
Bicocca, Milano, Italy
Matti Viluksela, Prof. Dr., former member SCHeR, National 
Institute for Health and Welfare Department of environmen-
tal Health, Kuopio, Finland and University of eastern Finland 
Department of environmental Science Kuopio, Finland
Wolfgang Völkel, PD Dr., eRt, Bayerisches landesamt 
für Gesundheit und lebensmittelsicherheit, Sachgebiet 
Chemikaliensicherheit und toxikologie/Biomonitoring, 
München, Germany
J. C. Vos, Dr., Dept. of Chemistry & Pharmacochemistry, 
AIMMS-Section of Molecular toxicology, Vrije Universiteit, 
Amsterdam, the Netherlands
Wojciech Wasowicz, Prof. Dr., President of the Polish Society 
of toxicology, Nofer Institute of Occupational Medicine, 
lodz, Poland
Hannu Komulainen, Research professor, former member 
SCHeR, National Institute for Health and Welfare, Depart-
ment of environmental Health, Kuopio, Finland
Hans lepper, Dr., Bayerisches landesamt für Gesundheit und 
lebensmittelsicherheit, SG K3: Forschungskoordination/
Zentralstelle Risikoanalyse, erlangen, Germany
Beatriz Silva lima, Prof. Dr., lisbon University, Faculty of 
Pharmacy, lisbon, Portugal
Jan linders, Dr., member SCHeR, formerly National 
Institute for Public Health and the environment (RIVM), the 
Netherlands
Marcello lotti, MD, Professor, University of Padua, Medical 
School, Padua, Italy
Marina Marinovich, Prof. Dr., Faculty of Pharmaceutical 
Sciences, lab. toxicology, Department of Pharmacological 
and Biomolecular Sciences, University of Milan, Italy
Angelo Moretto, Prof. Dr., Department of Biomedical and 
Clinical Sciences, Università degli Studi di Milano, Milano, 
Italy
Paquale Mosesso, Associate Professor of Genetics, member 
ANS Panel of eFSA, Department of ecological and Biologi-
cal Sciences, University of tuscia, Viterbo, Italy
Mikko Nikinmaa, Prof. Dr., Department of Biology, University 
of turku, Finland
Marc Pallardy, Prof. Dr., INSeRM UMR 996, University Paris-
Sud, Faculty of Pharmacy, Chatenay-Malabry, France
Markku Pasanen, Prof. Dr., University of eastern Finland, 
Faculty of Health Sciences, School of Pharmacy, Kuopio, 
Finland
Olavi Pelkonen, Professor of Pharmacology, Department of 
Pharmacology and toxicology, University of Oulu, Oulu, 
Finland
Hannu Raunio, Prof. Dr., University of eastern Finland, Faculty 
of Health Sciences, School of Pharmacy, Kuopio, Finland
Ivonne M.C.M. Rietjens, Prof. dr. ir., Professor in toxicology, 
member ANS Panel of eFSA, Wageningen University AFSG/ 
Division of toxicology, Wageningen, the Netherlands
Konrad Rydzynski, Prof. Dr. med., Coordinator of the euro-
pean Network of excellence eCNIS (environmental Cancer 
Risks, Nutrition and the Individual Susceptibility), member 
SCeNIHR, Director of the Nofer Institute of Occupational 
Medicine, lodz, Poland
edward V. Sargent, Dr., MPH, PhD DABt, Adjunct Full 
Professor, School of Public Health, Rutgers University, 
NJ, USA
tinaa Santonen, MD, PhD, MSc in Applied toxicology team 
leader, Chemical Safety, Finnish Institute of Occupational 
Health, Finland
